Eurofins Scientific Overview
Eurofins Scientific is the world's largest independent bioanalytical testing network. Its brand line is "Testing for Life". From a single Nantes laboratory that commercialised the SNIF-NMR isotopic method for authenticating wine and juice, it has grown into a decentralised federation of more than 1,000 companies. These test food, feed, water, soil, air, pharmaceuticals, medical devices, cosmetics, consumer goods, advanced materials and human clinical samples. FY2025 revenue was €7,296m and adjusted EBITDA was €1,641m (a 22.5% margin). Through Eurofins EAG Laboratories, MASER Engineering, Eurofins FQL and Chip Test Solutions, the group runs one of the largest independent materials-characterisation, failure-analysis, reliability and automated test equipment (ATE) networks serving semiconductor fabs, fabless designers, OSATs and equipment makers. That is why the group appears in assessments of the semiconductor quality and certification services market. Two transactions are sharpening the portfolio around life-science testing: the 2026 sale of the Electrical & Electronic Testing business (MET Labs) to UL Solutions for €575m, and the US$400m purchase of Element Materials Technology's North American Life Sciences Testing Services. Materials and semiconductor testing stay in the group.
What the company does
Eurofins provides analytical testing and related laboratory services. Its own description is a network that "offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity" of a wide range of products. It also provides "innovative clinical diagnostic testing services and in-vitro diagnostic products". Management calls Eurofins a global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience. It describes the group as one of the market leaders in certain genomics services, clinical-study support and biopharma contract development and manufacturing (CDMO). Management adds that it has a fast-developing presence in specialised and molecular clinical diagnostics and in in-vitro diagnostic (IVD) products.
Business model
The model rests on four design choices:
-
Decentralised, entrepreneurial structure. More than 1,000 legal entities run with local profit-and-loss accountability under empowered leaders. Group-wide functions (IT, finance, real estate, procurement) are centralised.
-
Hub-and-spoke laboratory network. Large, highly automated hub laboratories, increasingly in owned campuses, are fed by spoke laboratories, sample-collection points and logistics. This lowers unit costs and shortens turnaround times. The group's five-year investment programme (2023–2027) is built around completing this network and digitalising it end to end.
-
Proprietary digital stack. In-house laboratory information management systems (including the commercial LIMS, ComLIMS), customer portals and automation. Management treats this as a core competitive moat.
-
Capital-intensive build-out. About 345 start-up laboratories and 141 blood collection points (BCPs) have been launched since 2000, alongside a steady pace of bolt-on acquisitions (40 business combinations in FY2025; 17 in H1 2026). Owned real estate is increasing, at 905,000 m² of the 1,878,000 m² total net floor area at end-2025.
Revenue model
Eurofins earns almost all of its revenue from services. The group reports revenue by service-line type:
Sample-based revenue: (fee per test or per sample). This is the core of the model, covering routine food, environment, product testing and clinical diagnostics.
Study-based revenue: (contract studies, mainly agroscience, discovery and preclinical).
FTE-based revenue: (Professional Scientific Services, where Eurofins scientists work at client sites, mainly in BioPharma).
Product-based revenue: (IVD kits, reagents, assays), which is a small share.
For FY2024, data-provider extracts of the annual report break this down as about €5.81bn sample-based, €521m study-based, €478m FTE-based and €139m product-based. Product sales are therefore about 2% of revenue. Subscription and licensing revenue is not material.
Value-chain position and customers
Eurofins is an outsourced quality, safety and compliance partner. Its customers include:
-
food and beverage manufacturers, retailers and ingredient suppliers;
-
environmental consultants, utilities, industrial operators and regulators;
-
pharmaceutical, biotech and medical-device companies at every stage from discovery to commercial batch release;
-
agrochemical and seed companies;
-
hospitals, physicians, payers and public screening programmes;
-
consumer-goods brands and retailers; and
-
in Consumer & Technology Products Testing, semiconductor and electronics companies, aerospace and defence contractors and advanced-materials producers.
The group has stated that its exposure to China is less than 20% of consolidated revenue. Peers cited in short-seller commentary have between 40% and 50%.
End markets served (business lines)
| Business line | FY2025 revenue (EUR Mn) | Share of FY2025 revenue | Main activities |
|---|---|---|---|
| Life | 3,043 | 41.7% | Food & Feed Testing, Environment Testing (including PFAS), Agroscience |
| BioPharma | 2,062 | 28.3% | BioPharma Product Testing, Discovery & Genomics, CDMO, BioPharma Services, Medical Device Services, central-lab and bioanalysis |
| Diagnostic Services & Products | 1,496 | 20.5% | Routine and specialty clinical diagnostics (including the former SYNLAB Spain), transplant and infectious-disease testing (Viracor), IVD products |
| Consumer & Technology Products Testing | 695 | 9.5% | Consumer Product Testing (softlines, hardlines, cosmetics, toys), Materials & Engineering Sciences (EAG, MASER, FQL), Electrical & Electronic Testing (MET Labs, divested October 2026) |
Life: FY2025 revenue (€m): 3,043; Share of FY2025 revenue: 41.7%; Main activities: Food & Feed Testing, Environment Testing (including PFAS), Agroscience
BioPharma: FY2025 revenue (€m): 2,062; Share of FY2025 revenue: 28.3%; Main activities: BioPharma Product Testing, Discovery & Genomics, CDMO, BioPharma Services, Medical Device Services, central-lab and bioanalysis
Diagnostic Services & Products: FY2025 revenue (€m): 1,496; Share of FY2025 revenue: 20.5%; Main activities: Routine and specialty clinical diagnostics (including the former SYNLAB Spain), transplant and infectious-disease testing (Viracor), IVD products
Consumer & Technology Products Testing: FY2025 revenue (€m): 695; Share of FY2025 revenue: 9.5%; Main activities: Consumer Product Testing (softlines, hardlines, cosmetics, toys), Materials & Engineering Sciences (EAG, MASER, FQL), Electrical & Electronic Testing (MET Labs, divested October 2026)
Independent characterisation
Eurofins is best understood as a scale testing platform that sits between the traditional testing, inspection and certification (TIC) groups (SGS, Bureau Veritas, Intertek) and the life-science contract research organisations (Charles River, Labcorp). Its revenue per employee, scientific intensity and BioPharma weighting (more than 30% of activity, according to management) separate it from inspection-heavy TIC peers. Its routine food, environmental and clinical testing gives it a more defensive, regulation-driven revenue base than the CROs. The semiconductor and materials franchise is small within the group (well under 10% of revenue) but technically differentiated. EAG describes itself as the world-leading independent materials-characterisation and engineering resource for semiconductor testing, with techniques such as SIMS, TEM/FIB and plasma FIB, failure analysis, reliability qualification and production ATE.
Strategy
Stated strategy
Eurofins' strategy, as set out in the 2025 Annual Report and at the 2025 North American and European Investor Days, rests on these themes:
-
"Testing for Life" focus. Capital goes to core testing activities across the product lifecycle (food, environment, pharmaceutical, clinical and related testing). Non-core ancillary businesses are divested where they lack scale or fit, as with MET Labs and the Dutch clinical units.
-
Five-year investment programme (2023–2027) in a hub-and-spoke network. Large, automated, owned hub campuses connected to spoke laboratories and BCPs.
-
Full digitalisation. Proprietary LIMS, client portals, robotics and AI across laboratory workflows. These are named as uses of the MET Labs proceeds.
-
Owning strategic real estate. About €200m a year in 2026 and 2027 to buy or build the group's larger sites, up to €1bn over 2023–2027. Related-party leases are being phased out.
-
Disciplined M&A. Bolt-on acquisitions targeting about €250m of acquired revenue a year, supplemented by selective larger deals such as SYNLAB Spain and Element.
-
Start-up engine. New laboratories and BCPs that typically become profitable within a few years and add 0.4–0.6 points of organic growth a year.
-
Shareholder returns. Ongoing buybacks (5.5% of capital repurchased in FY2025) and a dividend growing in line with EPS.
Strategic initiatives in the last 24 months
| Initiative | Date | Details |
|---|---|---|
| SYNLAB Spain acquisition | Signed 2024, closed March 2025 | About €140m of FY2024 revenue; largest FY2025 acquisition |
| Related-party site purchases | AGM vote April 2025; completed September 2025 | Investment of €298m; 239,000 m² of campuses acquired; once remaining leases expire, all material related-party real-estate transactions end |
| Balance-sheet refinancing | March–July 2025 | €400m hybrid bond, €500m Schuldschein and €500m 7.5-year senior bond |
| Clinical diagnostics rationalisation | 2025–2026 | Exit from the Netherlands, contract pruning in Spain and Italy |
| MET Labs divestment | Announced April 2026, completed October 2026 | Enterprise value €575m; proceeds go to debt reduction, laboratory capex, digital, robotics and AI, buybacks and acquisitions |
| Element North America Life Sciences acquisition | Announced July 2026, closed October 2026 | US$400m for 27 laboratories, expanding coverage in under-represented US and Canadian regions |
| Seventh buyback programme | Launched 24 April 2026 | Up to 4.5% of capital |
| Carbon neutrality | Achieved 2025 | Covers Scope 1 and 2, business travel and commuting |
| Renewable power | 2024 onwards | Virtual power purchase agreement for Spanish solar capacity, in partnership with Thermo Fisher Scientific; designed to cover more than 15% of global electricity consumption |
| AI in the laboratory | 2,026 | AI-enabled solid-form screening at Alphora; continuous-flow API technology |
SYNLAB Spain acquisition: Date: Signed 2024, closed March 2025; Details: About €140m of FY2024 revenue; largest FY2025 acquisition
Related-party site purchases: Date: AGM vote April 2025; completed September 2025; Details: Investment of €298m; 239,000 m² of campuses acquired; once remaining leases expire, all material related-party real-estate transactions end
Balance-sheet refinancing: Date: March–July 2025; Details: €400m hybrid bond, €500m Schuldschein and €500m 7.5-year senior bond
Clinical diagnostics rationalisation: Date: 2025–2026; Details: Exit from the Netherlands, contract pruning in Spain and Italy
MET Labs divestment: Date: Announced April 2026, completed October 2026; Details: Enterprise value €575m; proceeds go to debt reduction, laboratory capex, digital, robotics and AI, buybacks and acquisitions
Element North America Life Sciences acquisition: Date: Announced July 2026, closed October 2026; Details: US$400m for 27 laboratories, expanding coverage in under-represented US and Canadian regions
Seventh buyback programme: Date: Launched 24 April 2026; Details: Up to 4.5% of capital
Carbon neutrality: Date: Achieved 2025; Details: Covers Scope 1 and 2, business travel and commuting
Renewable power: Date: 2024 onwards; Details: Virtual power purchase agreement for Spanish solar capacity, in partnership with Thermo Fisher Scientific; designed to cover more than 15% of global electricity consumption
AI in the laboratory: Date: 2026; Details: AI-enabled solid-form screening at Alphora; continuous-flow API technology
Medium-term financial objectives (as reiterated on 21 October 2026)
| Objective | FY2026 | FY2027 and mid-term |
|---|---|---|
| Organic growth | Below the original "mid-single-digit" target | Return to mid-single-digit growth in FY2027; long-term average of 6.5% a year |
| Acquired revenue | Above €250m annualised (including Element) | About €250m a year |
| Adjusted EBITDA margin | Above FY2025's 22.5% | 24% |
| SDI at EBITDA level | Lower than FY2025's €80m | About 0.5% of revenue |
| Cash conversion (FCFF / reported EBITDA) | FCFF growth with strong conversion | Above 50% |
| Leverage (net debt / pro-forma adjusted EBITDA) | Within range | 1.5x–2.5x, trending towards the lower end |
| Net operating capex | About €400m a year | About €400m a year |
| Investment in owned sites | About €200m | About €200m |
Organic growth: FY2026: Below the original "mid-single-digit" target; FY2027 and mid-term: Return to mid-single-digit growth in FY2027; long-term average of 6.5% a year
Acquired revenue: FY2026: Above €250m annualised (including Element); FY2027 and mid-term: About €250m a year
Adjusted EBITDA margin: FY2026: Above FY2025's 22.5%; FY2027 and mid-term: 24%
SDI at EBITDA level: FY2026: Lower than FY2025's €80m; FY2027 and mid-term: About 0.5% of revenue
Cash conversion (FCFF / reported EBITDA): FY2026: FCFF growth with strong conversion; FY2027 and mid-term: Above 50%
Leverage (net debt / pro-forma adjusted EBITDA): FY2026: Within range; FY2027 and mid-term: 1.5x–2.5x, trending towards the lower end
Net operating capex: FY2026: About €400m a year; FY2027 and mid-term: About €400m a year
Investment in owned sites: FY2026: About €200m; FY2027 and mid-term: About €200m
The 2023–2024 version of the 2027 plan also included revenue "approaching €10bn" and FCFF before owned sites "approaching €1.5bn". The current published objectives focus on margin, cash conversion and returns and no longer give an absolute revenue figure.
Products & Services
Eurofins sells through hundreds of locally branded companies under the "Eurofins" umbrella. The most important platforms are listed below by business line. Pricing is per test, per study or per FTE, and Eurofins does not publish price lists, so pricing is not publicly disclosed beyond these structures.
Life
| Offering | Description and capabilities | Target customers | Notable recent developments |
|---|---|---|---|
| Eurofins Food & Feed Testing | Microbiology, contaminants (pesticides, mycotoxins, heavy metals), allergens, GMO, nutritional labelling, authenticity (SNIF-NMR, isotope ratio MS), food-contact materials | Food manufacturers, retailers, ingredient traders, regulators | Cereulide toxin test by LC-MS/MS under ISO 18465:2017 (FY2025); APAC food testing grew double digits in 2026 |
| Eurofins Food Assurance / Sustainability Services | Audits, certification, supplier assurance, origin verification | Brands and retailers | Origin ID™ cotton-origin verification (FY2025) |
| Eurofins Environment Testing | Water, soil, air, waste, asbestos, emerging contaminants including PFAS; field sampling | Utilities, consultants, industry, government | PFAS testing grew double digits in North America in H1 2026; two environmental acquisitions (France, US) after 1 July 2026 |
| Eurofins Agroscience Services | Regulatory field trials, residue, environmental-fate and ecotoxicology studies for crop-protection registration | Agrochemical and seed companies | Activity was soft in 2024–2025 because of agrochemical destocking |
BioPharma
| Offering | Description and capabilities | Target customers | Notable recent developments |
|---|---|---|---|
| BioPharma Product Testing (BPT), including Lancaster Laboratories | GMP release and stability testing, method development and validation, raw-material and container testing, biologics characterisation; Professional Scientific Services® (FTE model) | Pharma, biotech, generics | Grew mid-single digits in Q3 2026 |
| Eurofins Discovery (DiscoverX, Cerep heritage) | In-vitro pharmacology, safety panels, kinase and GPCR assays, drug-discovery services | Pharma and biotech R&D | Returned to positive growth in Q3 2026 |
| Eurofins Genomics | Oligonucleotide synthesis, DNA sequencing (Sanger, NGS), genotyping | Academic and industrial researchers | Part of "Discovery & Genomics" |
| Eurofins CDMO (including Alphora, Canada) | Small-molecule API development and manufacturing, solid-form screening, formulation | Biotech and specialty pharma | AI-enabled salt and co-crystal screening developed with a local university (H1 2026); integration of in-house continuous-flow API technology (2026); CDMO revenue improved in Q3 2026 after a weak H1 |
| Central Lab, BioAnalysis and Clinical Trial Services | Clinical-trial sample testing, PK/PD bioanalysis, immunogenicity | CROs and sponsors | Temporary disruption in Q1 2026 from a BioAnalysis facility move; some clinical programmes are not expected to restart in 2026 |
| Eurofins Medical Device Services | Biocompatibility, sterility, extractables and leachables, packaging validation | Medical-device makers | GMP PFAS testing and screening for medical devices, the first offering of its kind according to the group (FY2025) |
| Element North America Life Sciences Testing (acquired 1 Oct 2026) | BioPharma product testing, environmental and food testing across 27 laboratories and facilities | US and Canadian pharma, food and environmental clients | More than US$150m of expected 2026 revenue; profitability similar to the group average |
Diagnostic Services & Products
| Offering | Description and capabilities | Target customers | Notable recent developments |
|---|---|---|---|
| Routine clinical diagnostics (France, Benelux, Spain, Italy, others) | Routine pathology through laboratories and blood collection points | Patients, physicians, hospitals, payers | SYNLAB Spain integrated from March 2025; contract rationalisation in Spain and Italy in 2026 |
| Eurofins Biomnis (France) | Specialty and esoteric testing | Laboratories and hospitals | Clinical LC-MS/MS cereulide method for stool samples (2026) |
| Eurofins Viracor (US) | Transplant, infectious-disease and immunology testing | Transplant centres and hospitals | Plasma-based CXCL9, CXCL10 and IL-18 assays with 24-hour turnaround (H1 2026) |
| Ascend Clinical (US) | Testing for kidney dialysis | Dialysis providers | Acquired 2024 |
| Clinical genetics and molecular diagnostics | Hereditary and oncology genetics, transplant genomics | Physicians and health systems | Hantavirus molecular and serological testing expanded, including the Andes strain (H1 2026) |
| IVD products (Eurofins Technologies and others) | ELISA, PCR and rapid-test kits for food, veterinary and clinical use | Laboratories | Product-based revenue is about 2% of the group total |
Consumer & Technology Products Testing
| Offering | Description and capabilities | Target customers | Notable recent developments |
|---|---|---|---|
| Eurofins Consumer Product Testing (softlines, hardlines, toys, cosmetics) | Chemical, physical, safety and performance testing; regulatory compliance | Brands, retailers, sourcing offices | Investment in Vietnam testing capacity (late 2025); strong growth in the Rest of the World in 2026 |
| Eurofins EAG Laboratories (HQ Sunnyvale, California) | Surface and bulk materials characterisation (SIMS, XPS, TOF-SIMS, GDMS, ICP-MS, laser ablation), advanced microscopy (TEM, FIB, plasma FIB, SEM), NanoIR, zeta potential, electrochemical impedance spectroscopy; more than 150 materials-testing techniques and more than 2,500 instruments | Semiconductor fabs and IDMs, fabless designers, equipment and materials suppliers, battery and EV makers, medical-device and aerospace firms | New 6,800 sq ft microscopy laboratory in Phoenix, Arizona; Korea laboratory opened; China laboratory (2023); battery laboratories in Sunnyvale and Syracuse (2024) |
| EAG Engineering Sciences: failure analysis | Root-cause failure analysis of ICs and components; defect characterisation (metal migration, voids, particles, cracks, delamination) | Semiconductor and electronics OEMs | Investment in precision imaging and inspection tools |
| EAG ATE Testing & Engineering (including Chip Test Solutions) | Test-program development, wafer sort, packaged-part and production testing on Advantest (V93000/EXA Scale) and Teradyne (UltraFLEXplus) platforms; digital to RF | Fabless companies, start-ups, IDMs | Chip Test Solutions acquired 5 January 2022; new EXA Scale and UltraFLEXplus systems added |
| EAG reliability qualification | ESD and latch-up testing, burn-in (Aehr HP Tahoe system for high- and low-power devices), HTOL, environmental stress | Semiconductor suppliers, automotive and aerospace qualification | Burn-in capacity expanded for power semiconductors |
| Eurofins MASER Engineering (Netherlands) | Reliability testing and failure analysis for semiconductors and electronic systems since 1993 | European semiconductor and electronics firms | Member of the Silicon Saxony cluster |
| Eurofins FQL (Japan) | Reliability, failure and materials analysis; founded in 1994 as Fujitsu Analysis Laboratory | Japanese semiconductor and electronics groups | — |
| Eurofins Nanolab Technologies | 3D nanoscale imaging of semiconductor films | Semiconductor R&D | — |
| Electrical & Electronic Testing (MET Labs) | Product safety, EMC and wireless testing, inspection and certification | Consumer electronics, automotive, telecoms, industrial | Sold to UL Solutions, completed 2 October 2026 |
Financial Narrative
All figures are company-reported (FY2021–FY2025 annual results releases and annual reports) unless stated otherwise. Eurofins presents its income statement by nature of expense and does not report gross profit. EBITDA as Eurofins defines it excludes share-based payment charges, acquisition-related expenses and gains or losses on disposals. "Adjusted" figures exclude separately disclosed items (SDI), which mainly reflect start-ups and businesses still being restructured.
Income statement
Reported EBITAS was €1,389m in FY2021 and €911m in FY2022. Adjusted EBITAS was €1,473m and €1,037m in those years.
Margins and growth
Revenue CAGR from FY2021 to FY2025 was 2.1%. That figure is heavily distorted by COVID-19 testing revenue, which fell from more than €1.4bn in FY2021 to just under €600m in FY2022 and about €20m in FY2023. On a Core Business basis (excluding COVID), revenue rose from €5,292m in FY2021 to €7,296m in FY2025, a CAGR of about 8.4% including acquisitions. Organic growth on that basis was 5.8% in FY2022 and 7.1% in FY2023 (both adjusted for working days), followed by 4.7% (FY2024) and 3.7% (FY2025).
Commentary.
2021 to 2023 normalisation: The adjusted EBITDA margin fell from 28.3% to 20.9% as high-margin COVID PCR volumes disappeared. At the same time the group invested heavily: net capex of €645m in FY2022, 50 start-up laboratories, and bespoke IT and owned sites. Euro strength added FX headwinds.
2023 to 2025 recovery: Margins rebuilt by 160bps (adjusted) and 250bps (reported), helped by shrinking SDI (€113m in FY2024, €80m in FY2025) as start-ups matured. Net profit rose 54% over two years and basic EPS rose 74%, helped by buybacks that cut the basic weighted share count from 191m to 180m.
2026 inflection: In H1 2026 the adjusted EBITDA margin was 23.7%, 130bps higher year on year and already close to the 24% target for 2027. Reported EBITDA margin was 23.3%, and basic EPS rose 29% to €1.55 on organic growth of only 2.7%. Two one-off legal settlement gains totalling €19m helped. Excluding them, SDI still fell.
Half-year and quarterly trend (2025–2026)
Nine-month 2026 revenue was €5,614m (+3.7%), with organic growth of 3.0%, an FX headwind of 1.7% and a 0.7% drag from discontinued activities and disposals. Q3 2026 revenue of €1,913m was 6.1% above Q3 2025.
Balance sheet
Line items other than net debt follow the standardised presentation of the consolidated balance sheet. Net debt is the company-reported figure. The high cash balance at end-2023 reflects pre-funding ahead of the July 2024 Eurobond maturity (€448m), which was repaid early on 19 June 2024. The fall in equity in FY2025 reflects €541m of net share buybacks, translation losses from the weaker US dollar and the accounting for hybrid capital refinancing. Hybrid bonds are classified 100% as equity under IFRS. Goodwill and intangibles were about 49% of total assets at end-2025.
Cash flow
FY2021 FCFF was first published as €1,015m and was presented as €1,030m in the FY2022 comparatives. The later figure is used above.
FY2025 capex split into net operating capex of €328m (€365m in FY2024) and investment in owned sites of €195m (€154m). The group also made a separate €298m purchase of related-party-owned campuses. Cash dividends to shareholders were €110m in FY2025 (€98m in FY2024). Net share buybacks were €541m (€272m). Gross buybacks were €559m for 10,693,660 shares at an average €52.24, or about 5.5% of the share capital. In H1 2026, FCFF rose 46% to €403m and FCFF before owned sites rose 33% to €469m. Cash conversion improved to 47% from 36%, reflecting lower capex (€212m against €251m) and tighter working capital (net working capital intensity of 4.9% against 5.5%).
Ratios
Other return and coverage measures:
- Return on capital employed (ROCE) including goodwill, the company's preferred return measure, rose to 12.8% in FY2025 from 12.2% in FY2024.
Interest coverage: reported EBIT was 4.5x total finance costs in FY2024 (€681m / €151m) and 4.7x in FY2025 (€784m / €166m). On net finance costs it was 5.4x and 6.0x.
Working capital: net working capital intensity (net working capital divided by four times last-quarter sales) was 4.5% in FY2021, 4.2% in FY2022 and 5.1% in FY2023, and fell to 4.9% by June 2026. Inventory is negligible (about €140m), so the cash conversion cycle is effectively receivables-led and close to the 82–91 receivables days shown above.
Trend drivers. Returns bottomed in FY2023, when the COVID windfall had ended but the investment programme was at its peak. The recovery since then has three causes: (i) start-up and network-build costs (SDI) falling towards 0.5% of revenue; (ii) owned hub campuses replacing leases and lowering occupancy costs; and (iii) digitalisation lifting productivity. Leverage rose to 2.2x at end-2025 and stayed there at June 2026. This followed record buybacks, the €298m related-party real-estate purchase and SYNLAB Spain. The two Q4 2026 transactions (€575m MET Labs proceeds against the US$400m Element purchase) are roughly leverage-neutral to slightly deleveraging.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 6,718 | 6,712 | 6,515 | 6,951 | 7,296 |
Adjusted EBITDA (EUR Mn) | 1,902 | 1,513 | 1,364 | 1,552 | 1,641 |
Reported EBITDA (EUR Mn) | 1,840 | 1,415 | 1,234 | 1,439 | 1,561 |
Adjusted net profit (EUR Mn) | 1,043 | 683 | 568 | 687 | 725 |
Reported net profit (EUR Mn) | 783 | 606 | 308 | 405 | 473 |
Basic EPS reported (EUR) | 3.91 | 3.02 | 1.33 | 1.87 | 2.31 |
Diluted EPS attributable to owners (EUR) | 3.73 | 2.92 | 1.30 | 1.83 | 2.23 |
Adjusted basic EPS (EUR) | 5.29 | 3.43 | 2.71 | 3.37 | 3.72 |
Dividend per share (EUR) | 1.00 | 1.00 | 0.50 | 0.60 | 0.72 |
Operating-profit metric
| Operating-profit metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Adjusted EBITAS (EUR Mn) | 842 | 1,017 | 1,079 |
Reported EBITAS (EUR Mn) | 669 | 843 | 931 |
Reported EBIT (EUR Mn) | 530 | 681 | 784 |
Net finance costs (EUR Mn) | 107 | 127 | 131 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Adjusted EBITDA margin (%) | 28.3 | 22.5 | 20.9 | 22.3 | 22.5 |
Reported EBITDA margin (%) | 27.4 | 21.1 | 18.9 | 20.7 | 21.4 |
Reported net margin (%) | 11.7 | 9.0 | 4.7 | 5.8 | 6.5 |
Reported revenue growth (%) | 23.5 | -0.1 | -2.9 | 6.7 | 5.0 |
Reported basic EPS growth (%) | 44 | -23 | -56 | 41 | 24 |
Income Statement and Per-Share Data (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Revenue (EUR Mn) | 3,612 | 3,701 |
Adjusted EBITDA (EUR Mn) | 810 | 877 |
Reported EBITDA (EUR Mn) | 773 | 862 |
Reported EBITAS (EUR Mn) | 464 | 564 |
Reported net profit (EUR Mn) | 247 | 302 |
Basic EPS (EUR) | 1.20 | 1.55 |
Operating cash flow (EUR Mn) | 526 | 614 |
Net capex (EUR Mn) | 251 | 212 |
FCFF (EUR Mn) | 276 | 403 |
Net debt at period end (EUR Mn) | 3,360 | 3,854 |
Income Statement and Margin Analysis (%)
| Metric | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|
Revenue (EUR Mn) | 1,789 | 1,912 | 1,913 |
Organic growth (%) | 2.5 | 3.0 | 3.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR Mn) | 9,332 | 10,084 | 10,889 | 10,888 | 10,985 |
Cash and equivalents (EUR Mn) | 515 | 487 | 1,221 | 614 | 791 |
Current borrowings (EUR Mn) | 80 | 79 | 0 | 83 | 247 |
Non-current borrowings (EUR Mn) | 2,082 | 2,713 | 2,889 | 2,674 | 3,407 |
Total debt including leases (EUR Mn) | 2,754 | 3,326 | 3,927 | 3,610 | 4,432 |
Net debt (EUR Mn) | 2,239 | 2,839 | 2,705 | 2,996 | 3,641 |
Total equity including hybrid capital (EUR Mn) | 4,677 | 4,851 | 5,137 | 5,385 | 4,577 |
Goodwill (EUR Mn) | 4,115 | 4,524 | 4,551 | 4,841 | 4,657 |
Other intangible assets (EUR Mn) | 896 | 919 | 796 | 788 | 690 |
Working capital, current assets less current liabilities (EUR Mn) | 463 | 541 | 945 | 342 | 224 |
Cash Flow and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net cash from operating activities (EUR Mn) | 1,510 | 1,136 | 1,018 | 1,319 | 1,399 |
Net capex (EUR Mn) | 482 | 645 | 544 | 518 | 522 |
FCFF (EUR Mn) | 1,030 | 491 | 474 | 801 | 876 |
FCFF before investment in owned sites (EUR Mn) | 1,142 | 677 | 626 | 954 | 1,071 |
Cash conversion, FCFF / reported EBITDA (%) | 56 | 35 | 38 | 56 | 56 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, reported net profit / year-end equity (%) | 16.7 | 12.5 | 6.0 | 7.5 | 10.3 |
ROA, reported net profit / total assets (%) | 8.4 | 6.0 | 2.8 | 3.7 | 4.3 |
Current ratio (x) | 1.25 | 1.31 | 1.44 | 1.16 | 1.09 |
Total debt / equity (x) | 0.59 | 0.69 | 0.76 | 0.67 | 0.97 |
Net debt / pro-forma adjusted EBITDA (x) | 1.2 | 1.9 | 2.0 | 1.9 | 2.2 |
Asset turnover, revenue / total assets (x) | 0.72 | 0.67 | 0.60 | 0.64 | 0.66 |
Receivables days, year-end receivables / revenue × 365 | 86 | 87 | 91 | 84 | 82 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Europe revenue (EUR Mn) | 3,306 | 3,549 | 3,829 |
North America revenue (EUR Mn) | 2,507 | 2,660 | 2,685 |
Rest of the World revenue (EUR Mn) | 701 | 742 | 782 |
Revenue by Region (%)
| Region (%) | FY2025 organic growth (%) | H1 2026 organic growth (%) | 9M 2026 organic growth (%) | 9M 2026 share of revenue (%) |
|---|---|---|---|---|
Europe | 3.3 | 2.0 | 1.9 | 52 |
North America | 2.8 | 2.0 | 2.8 | 36 |
Rest of the World | 9.0 | 9.1 | 9.3 | 11 |
Share Price & Returns
| Reference point | Share price (EUR) |
|---|---|
IPO, 24 October 1997 (split-adjusted) | 0.183 |
31 December 2025 close | 62.40 |
22 April 2026 (Q1 release day close) | 69.36 |
30 June 2026 (H1 2026: +9.9% against CAC 40 +3.1%) | about 68.6 |
21 October 2026 intraday four-year high | 81.54 |
Early November 2026 | mid-80s |
Valuation Snapshot
| Multiple | Value |
|---|---|
P/E on FY2025 reported basic EPS (€2.31) | 36.8 |
P/E on FY2025 adjusted basic EPS (€3.72) | 22.8 |
P/E on 2026 consensus EPS (€4.04) | 21.0 |
EV / FY2025 adjusted EBITDA (EV about €18.8bn including June 2026 net debt of €3.85bn) | 11.5 |
EV / FY2025 revenue | 2.6 |
P/B on FY2025 total equity (€4.58bn, including hybrid capital) | 3.3 |
Dividend yield (FY2025 €0.72 DPS) (%) | 0.8 |
Cash Flow
| Consensus metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
Revenue (EUR Mn) | 7,534 | 7,942 | 8,472 |
Net debt (EUR Mn) | 3,445 | 3,100 | 2,839 |
Net capex (EUR Mn) | 563 | 603 | 612 |
Consensus per-share metric (%)
| Consensus per-share metric (%) | FY2026E | FY2027E |
|---|---|---|
EPS (EUR) | 4.04 | 4.38 |
Dividend per share (EUR) | 0.81 | 0.92 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (EUR) | 1.00 | 1.00 | 0.50 | 0.60 | 0.72 |
Payout on reported basic EPS (%) | 26 | 33 | 38 | 32 | 31 |
Share Price & Returns by Period
| Period | Shares repurchased | Average price (EUR) | Amount |
|---|---|---|---|
FY2024 | 5.85m | 49.60 | €290m gross (€272m net) |
FY2025 | 10,693,660 | 52.24 | €559m gross (€541m net); 5.5% of capital |
H1 2026 | 3,653,476 | 63.04 | €230m gross (€206m net) |
Credit Ratings
| Agency | Rating | Outlook | First assigned |
|---|---|---|---|
Moody's (issuer and senior unsecured) | Baa3 | Stable (affirmed) | July 2020 |
Moody's (subordinated hybrid) | Ba2 | Stable | — |
Fitch (long-term issuer) | BBB- | Stable | May 2021 |
Capital Instruments
| Instrument | Amount | Terms |
|---|---|---|
Senior Eurobond | €302m | Matured 17 July 2026 |
Schuldschein loans (June 2025 issue) | €500m | 3.8% blended rate; multiple tranches |
Senior unsecured bonds (July 2025) | €500m | 7.5-year tenor (maturing early 2033) |
Hybrid bonds (March 2025) | €400m | Perpetual; 100% equity under IFRS, 50% equity credit at Moody's and Fitch |
Other senior Eurobonds and earlier hybrid series | Not itemised here | Staggered maturities across 2027–2031 |
Committed undrawn bank lines | More than €1bn | Liquidity backstop |
Net debt (30 June 2026) | €3,854m | 2.2x pro-forma adjusted EBITDA |
Analyst Conclusions
Management guidance (21 October 2026)
| Item | FY2026 | FY2027 |
|---|---|---|
| Organic growth | Below mid-single digit | Return to mid-single digit; long-term average 6.5% |
| Acquired revenue | Above €250m annualised, including Element | About €250m |
| Adjusted EBITDA margin | Above 22.5% | 24% |
| SDI | Below €80m | About 0.5% of revenue |
| Cash | FCFF growth | Cash conversion above 50% |
| Leverage | Within 1.5x–2.5x | Towards the lower end of the range |
Organic growth: FY2026: Below mid-single digit; FY2027: Return to mid-single digit; long-term average 6.5%
Acquired revenue: FY2026: Above €250m annualised, including Element; FY2027: About €250m
Adjusted EBITDA margin: FY2026: Above 22.5%; FY2027: 24%
SDI: FY2026: Below €80m; FY2027: About 0.5% of revenue
Cash: FY2026: FCFF growth; FY2027: Cash conversion above 50%
Leverage: FY2026: Within 1.5x–2.5x; FY2027: Towards the lower end of the range
Consensus expectations
Consensus expects revenue of about €7.53bn in FY2026 (+3%), €7.94bn in FY2027 (+5%) and €8.47bn in FY2028 (+7%), and net debt falling to about €2.8bn by FY2028. EPS of €4.04 in FY2026 and €4.38 in FY2027 implies high-single to low-double-digit adjusted EPS growth, with buybacks and margins doing more of the work than volumes.
Bull case
-
Operating leverage ahead of schedule. The H1 2026 adjusted EBITDA margin of 23.7% means the 24% target for 2027 is effectively reached. Any recovery of organic growth towards 5–6% would therefore flow through at high incremental margins, supporting EPS growth of 15–25% a year.
-
The cash inflection is real. Cash conversion rose from 36% to 47% in H1 2026. Capex is past its peak (net operating capex of about €400m against EBITDA above €1.6bn), and investment in owned sites is set to fall after 2027. FCFF of more than €1bn should go increasingly to buybacks, which have already retired about 9% of shares since February 2025.
-
Portfolio discipline is raising quality. The MET Labs sale (about 3.2x sales) and the Element purchase (below 3x sales, at group-average margins) show disciplined capital rotation into core "Testing for Life" businesses. The semiconductor and materials franchise (Consumer & Technology growing 7.9% organically) adds structural growth that is rarely priced in.
Bear case
-
Organic growth is structurally impaired. Three consecutive years of growth below the 6.5% target (4.7%, 3.7% and about 3% in 9M 2026), a lowered FY2026 target and BioPharma near zero raise the question of whether the hub-and-spoke model gives up growth in exchange for margin.
-
Valuation already discounts delivery. At about 21x 2026 consensus EPS and about 11.5x EV/EBITDA after a roughly 40% one-year re-rating, the shares need both the margin target and a recovery in growth. Any slip in the BioPharma recovery could reverse the re-rating.
-
Governance and cyber tail risks. The founder-controlled structure, the record of short-seller attacks and two significant cyber incidents (2019, 2025) in a business handling sensitive clinical data leave the shares exposed to episodic de-ratings. Euro strength against the dollar is a recurring headwind to reported growth.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst |
|---|---|
| Late January 2027 | FY2026 results: confirmation of an adjusted EBITDA margin above 23%, FCFF growth and FY2027 guidance |
| Q4 2026 – Q1 2027 | Investor Days referred to by management |
| Q4 2026 onwards | First consolidated contribution from Element North America (more than US$150m of revenue) and removal of MET Labs |
| 2,027 | Pace of the recovery in ancillary BioPharma activities (CDMO, discovery, central lab) and in clinical-programme restarts |
| April 2027 | FY2026 dividend (consensus €0.81) and renewal of buyback authority at the AGM |
| 2,027 | Use of the MET Labs proceeds across debt reduction, buybacks and M&A |
| Ongoing | PFAS regulation, US clinical reimbursement changes, euro/dollar exchange rate, semiconductor capex cycle |
| Ongoing | Outcome of the Dutch investigation into the 2025 data breach |
Late January 2027: Catalyst: FY2026 results: confirmation of an adjusted EBITDA margin above 23%, FCFF growth and FY2027 guidance
Q4 2026 – Q1 2027: Catalyst: Investor Days referred to by management
Q4 2026 onwards: Catalyst: First consolidated contribution from Element North America (more than US$150m of revenue) and removal of MET Labs
2027: Catalyst: Pace of the recovery in ancillary BioPharma activities (CDMO, discovery, central lab) and in clinical-programme restarts
April 2027: Catalyst: FY2026 dividend (consensus €0.81) and renewal of buyback authority at the AGM
2027: Catalyst: Use of the MET Labs proceeds across debt reduction, buybacks and M&A
Ongoing: Catalyst: PFAS regulation, US clinical reimbursement changes, euro/dollar exchange rate, semiconductor capex cycle
Ongoing: Catalyst: Outcome of the Dutch investigation into the 2025 data breach
Analyst verdict
Eurofins in late 2026 is a business whose profitability story has run ahead of its growth story. The five-year programme of owned hub campuses, start-up laboratories and full digitalisation, launched as the COVID windfall faded, is now producing the margin and cash results management promised. The adjusted EBITDA margin rose from 20.9% in FY2023 to 23.7% in H1 2026. Basic EPS grew 24% in FY2025 and 29% in H1 2026, and cash conversion is moving towards the 50% target for 2027 as capex falls. The balance sheet has absorbed record buybacks, the €298m buyout of related-party campuses and steady bolt-on M&A while staying investment grade at 2.2x leverage. The 2026 portfolio moves, selling MET Labs for €575m and buying Element's North American life-sciences laboratories for US$400m, show capital being allocated deliberately rather than for size.
The weak point is volume. Organic growth has missed the 6.5% long-term ambition for three years running, and the FY2026 target was cut in October. BioPharma, the most scientifically valuable franchise, is barely growing, and clinical diagnostics is being shrunk to profitability. The better news is that growth has improved each quarter in 2026 (2.5%, 3.0% and 3.5%). BioPharma Product Testing and Discovery are improving, Life is growing about 4–5%, and the Consumer & Technology line, including the semiconductor-focused EAG, MASER and FQL laboratories, is growing close to 8%.
For investors in the semiconductor quality and certification ecosystem, Eurofins is not a pure play. Materials and semiconductor testing are a minority of a €7.3bn testing group. It is, however, a technically differentiated one, and the MET Labs exit leaves it as the core of the remaining technology-testing business. After a roughly 40% re-rating, the shares now price in most of the margin plan. Further gains depend on organic growth returning to mid-single digits in 2027. On balance, the company shows improving quality, high cash generation and credible capital allocation, with recovery of organic growth as the main condition for a further re-rating.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Board tenure | Background and education | Birth year |
|---|---|---|---|---|
Dr Gilles G. Martin | Chairman and Chief Executive Officer | Founder, CEO since 1987 | Computer Science Engineer, École Centrale Paris; MSc, Syracuse University; PhD in Statistics and Applied Mathematics. Former independent director of Bruker Corp. (2014–2020); former president of APROLAB and of the North American Technical Committee for Juice and Juice Products | 1963 |
Valérie Hanote | Executive Director | Long-serving | Responsible for the group's commercial laboratory information management system (ComLIMS); former spouse of Dr Gilles Martin | 1966 |
Dr Yves-Loïc Martin | Non-Executive Director | Executive role from 1992; non-executive since 1 January 2022 | Graduate of École Polytechnique; Master in Applied Mathematics (Paris VI); PhD in Chemometrics. Joined as Quality Assurance Manager (1992), Chief Technology Officer 1998–2015; now a deep-tech business angel; brother of the CEO | 1966 |
Pascal Rakovsky | Lead Independent Director; Chair, Audit and Risk Committee; member, Sustainability & Corporate Governance Committee | Since June 2020 | PwC Luxembourg audit partner from 1992 to 2015 (RTL Group, Millicom); director of Alter Domus and Foundever | 1959 |
Patrizia Luchetta | Independent non-executive director; Chair, Sustainability & Corporate Governance Committee; member, Audit and Risk Committee | Since 2017 | Experience in the food industry, environmental services and financial services in Luxembourg, Germany and the US; board member of LSH Management GP | 1964 |
Evie Roos | Independent non-executive director | Mandate proposed for renewal at the April 2026 AGM | Sustainability and reporting specialist; led the development of internal sustainability upskilling for the PwC network | — |
Erica Monfardini | Independent non-executive director; member, Audit and Risk Committee and Nomination and Remuneration Committee | Since April 2024 | Senior finance executive | 1971 |
Gavin Hill | Independent non-executive director; member, Audit and Risk Committee and Nomination and Remuneration Committee | Since April 2025 | CFO and Executive Director of Oxford Instruments plc (May 2016 – March 2025); earlier roles at Synergy Health, Serco, Syngenta and AstraZeneca; Chair of the Audit Committee of BMT Group | 1968 |
Valérie Arnold | Independent non-executive director | Since April 2026 | Appointed at the 23 April 2026 AGM | 1969 |
Executive Leadership Team
| Name | Role | Background |
|---|---|---|
Dr Gilles G. Martin | Chairman and CEO | See above |
Laurent Lebras | Group Finance & Administration Director (Group CFO) | Joined in 2015; HEC Paris; formerly CFO of L'Oréal Asia-Pacific and Japan, Finance Director of L'Oréal Korea, Gemey-Maybelline France and Energy Trading Corp. |
Gonzalo Mele | Group Chief Information Officer | Leads the digitalisation programme |
Dr Christian Wurst | Chief Operating Officer, Food & Environment Testing | Long-serving Eurofins operating leader |
Brian Williams | Group Operating Council member | Joined in 2017 after 30 years in TIC; formerly Group General Manager, Global Minerals Division, ALS Limited |
François Vigneau | Group Operating Council member; leads IT programmes for Food Testing | Institut National Agronomique Paris; formerly at Danone; President of APROLAB |
Sean Murray | Group Operating Council member; US Food Testing | Joined in 2016; built US food-testing market leadership |
Dr Timothy Oostdyk | Group Operating Council member; BioPharma | Former President of Lancaster Laboratories |
Gregg Tiemann | Group Operating Council member | — |
Joachim Reichelt | Group Operating Council member | Former CEO of Hofmann Menu (a Partners Group portfolio company); earlier at Eismann and Aryzta |
Yvoine Rémy | Group Operating Council member | — |
Directors' Remuneration
| Director | Fixed pay share (%) | Total remuneration (EUR K) |
|---|---|---|
Dr Gilles Martin (Chairman and CEO) | 27 | 5,155 |
Valérie Hanote (Executive Director) | 100 | 435 |
Dr Yves-Loïc Martin (Non-Executive) | 100 | 34 |
Board & Management Changes
| Date | Change |
|---|---|
Apr 2024 | Erica Monfardini appointed independent director |
Apr 2025 | Gavin Hill (former Oxford Instruments CFO) appointed independent director |
Feb 2026 | Senior clinical-diagnostics leader recruited from Unilabs to the Group Operating Council |
Apr 2026 | Valérie Arnold appointed independent director; mandates of Evie Roos and Patrizia Luchetta proposed for renewal |
Apr 2026 | Group CFO Laurent Lebras exercises stock options and sells 6,000 shares at an average €65.75 (€394,500), disclosed as a routine LTI-linked PDMR transaction |
Major Shareholders
| Holder | Share of capital (%) |
|---|---|
Martin family (mainly Analytical Bioventures SCA) | 36.5 |
Free float | 62.1 |
Treasury shares and other | 1.4 |
Competitive Landscape
Competitors by Segment
| Business line | Main competitors | Relative positioning |
|---|---|---|
Food & Feed Testing | SGS, Bureau Veritas, Intertek, Mérieux NutriSciences, ALS, Tentamus, NSF | Eurofins is generally regarded as the global number one in independent food testing by laboratory network scale |
Environment Testing | ALS, SGS, Pace Analytical, Montrose Environmental, Bureau Veritas | Leading US position since TestAmerica; strong European hubs; a leader in PFAS |
BioPharma Product Testing and services | Charles River Laboratories, SGS, Element (North American life sciences, now part of Eurofins), Labcorp, WuXi AppTec, Pace | Leader in outsourced GMP release testing; Professional Scientific Services model is a differentiator |
Discovery & Genomics, CDMO | Charles River, WuXi, Thermo Fisher (Patheon), Azenta (Genewiz), Lonza, Siegfried | Niche player in CDMO; strong in in-vitro safety pharmacology panels |
Clinical diagnostics | Quest Diagnostics, Labcorp, Cerba/SYNLAB, Unilabs, Sonic Healthcare | Specialty and esoteric strength (Viracor, Biomnis) with regional routine scale in France and Spain |
Consumer Product Testing | SGS, Intertek, Bureau Veritas, TÜV SÜD, QIMA | Second-tier scale compared with SGS and Intertek; fast growth in Asia |
Materials and semiconductor testing | MA-tek, Integrated Service Technology (iST), SGS, Intertek, TÜV SÜD, UL Solutions, Element, Applus+ | EAG claims world leadership in independent semiconductor materials characterisation; Asian peers MA-tek and iST lead in Taiwanese fab-adjacent failure analysis |
Electrical & Electronic TIC (exited October 2026) | UL Solutions, Intertek, SGS, TÜV Rheinland | Sold to UL Solutions |
Peer Comparison FY2025
| Metric | Eurofins | SGS | Bureau Veritas | Intertek |
|---|---|---|---|---|
Revenue (local currency, m) | 7296 (EUR) | 6945 (CHF) | 6466 (EUR) | 3432 (GBP) |
Organic / like-for-like growth (%) | 3.7 | 5.6 | 6.5 | 3.9 |
Adjusted operating margin (%) | 14.8 | 16.0 | 16.3 | 18.1 |
